title: Metabolic remission with octreotide in patients with insulinoma.
abstract: OBJECTIVE
  The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma.
  
  
  METHODS
  A phase-II study.
  
  
  METHODS
  A university department of internal medicine.
  
  
  METHODS
  Seven patients with biochemical evidence of insulinoma and without metastatic lesions.
  
  
  METHODS
  Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100-300 micrograms day-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken.
  
  
  RESULTS
  Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2-54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation.
  
  
  CONCLUSIONS
  Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.
authors.affiliation: Department of Internal Medicine and Endocrinology, Odense University Hospital, Denmark.
authors.forename: F E
authors.initials: FE
authors.lastname: von Eyben
authors.forename: E
authors.initials: E
authors.lastname: Grodum
authors.forename: H J
authors.initials: HJ
authors.lastname: Gjessing
authors.forename: C
authors.initials: C
authors.lastname: Hagen
authors.forename: H
authors.initials: H
authors.lastname: Nielsen
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007340:Insulinoma / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015282:Octreotide